News

Select Year
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.
June 7, 2021 7:05 PM
EDT
2021
Aurinia Announces Results of the 2021 Annual General Meeting
Download
June 7, 2021 7:04 AM
EDT
2021
Aurinia Announces Additional Analysis of its AURORA 1 Phase 3 Study Data Presented at ERA-EDTA 2021 Congress
Download
May 27, 2021 6:05 AM
EDT
2021
Aurinia Pharmaceuticals to Present at the Jefferies Virtual Healthcare Conference
Download
May 20, 2021 4:05 PM
EDT
2021
Aurinia To Present Supportive AURORA 2 Continuation Study Interim Analysis Demonstrating Long-Term Safety & Efficacy of LUPKYNIS™ (voclosporin) in Subjects with Lupus Nephritis
Download
May 14, 2021 6:05 AM
EDT
2021
Aurinia Pharmaceuticals to Participate in Two Upcoming Investor Conferences
Download
May 10, 2021 4:05 PM
EDT
2021
Aurinia Unveils Patient Navigation Grant Program to Address Access Barriers for Individuals Living with Lupus and Lupus Nephritis
Download
May 10, 2021 6:05 AM
EDT
2021
Aurinia Announces Publication of AURORA 1 Phase 3 Study Results with LUPKYNIS™ (voclosporin) in The Lancet
Download
May 6, 2021 4:05 PM
EDT
2021
Aurinia Reports First Quarter 2021 Financial Results and Recent Operational Highlights
Download
April 28, 2021 6:30 AM
EDT
2021
Aurinia Pharmaceuticals to Release First Quarter 2021 Financial Results on May 6, 2021
Download
April 15, 2021 6:05 AM
EDT
2021
Aurinia Pharmaceuticals to Present at the Bloom Burton & Co. Healthcare Investor Conference
Download
April 8, 2021 6:05 AM
EDT
2021
Aurinia Presents Data Demonstrating LUPKYNIS™ (voclosporin) Efficacy Across Lupus Nephritis Biopsy Classes at National Kidney Foundation 2021 Spring Clinical Meetings
Download
March 15, 2021 6:05 AM
EDT
2021
Aurinia Announces Positive Cost-Effectiveness Assessment of LUPKYNIS™ (voclosporin) in Latest ICER Draft Evidence Report
Download
March 3, 2021 6:05 AM
EST
2021
Aurinia Pharmaceuticals to Present at Three Upcoming March Investor Conferences
Download
February 24, 2021 4:02 PM
EST
2021
Aurinia Reports Fourth Quarter and Full Year 2020 Financial Results and Recent Operational Highlights
Download
February 18, 2021 6:05 AM
EST
2021
Aurinia Pharmaceuticals to Present at the SVB Leerink 10th Annual Global Healthcare Conference
Download
February 17, 2021 6:05 AM
EST
2021
Aurinia Pharmaceuticals to Release Fourth Quarter and Year End 2020 Financial Results on February 24, 2021
Download
January 22, 2021 8:24 PM
EST
2021
FDA Approves Aurinia Pharmaceuticals’ LUPKYNIS™ (voclosporin) for Adult Patients with Active Lupus Nephritis
Download
January 8, 2021 6:05 AM
EST
2021
Aurinia Pharmaceuticals to Present at Two Upcoming Virtual Healthcare Conferences
Download
December 17, 2020 4:00 AM
EST
2020
Aurinia Announces Collaboration and Licensing Agreement with Otsuka Pharmaceutical Co., Ltd. for the Development and Commercialization of Voclosporin in Europe and Japan
Download
December 15, 2020 5:59 PM
EST
2020
Aurinia and Lonza Announce Exclusive Agreement for Dedicated Voclosporin Manufacturing Capacity
Download
December 2, 2020 6:05 AM
EST
2020
Aurinia Pharmaceuticals to Present at the Piper Sandler 32nd Annual Virtual Healthcare Conference
Download
November 20, 2020 5:00 PM
EST
2020
Aurinia Announces New Employment Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Download
November 12, 2020 4:05 PM
EST
2020
Aurinia Pharmaceuticals to Present at the 2020 Jefferies Virtual London Healthcare Conference
Download
November 10, 2020 4:02 PM
EST
2020
Aurinia Reports Third Quarter 2020 Financial Results and Recent Operational Highlights
Download
November 9, 2020 4:05 PM
EST
2020
Aurinia Presents Integrated Time to Renal Response Data from the AURA-LV and AURORA Trials, along with Voclosporin Drug-Drug Interaction Data at ACR Convergence 2020
Download
No Results Found
Please try different keywords or filters.

Email Alerts

By providing your email address above, you are providing consent to Aurinia Pharmaceuticals Inc. to send you the requested Investor Email Alert updates. For information on how we protect your information, please refer to our Privacy Policy.
Thank you! Your message has been sent!
Oops! There was an error with your submission.